Vadastuximab talirine

Drug Profile

Vadastuximab talirine

Alternative Names: 33 A; Anti-CD33A targeted ADC - Seattle Genetics; SGN CD33A

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies; Pyrroles
  • Mechanism of Action Cytoadhesin receptor antagonists; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Myelodysplastic syndromes

Most Recent Events

  • 22 Jun 2017 Efficacy and adverse events data from a phase I trial in Acute myeloid leukaemia presented at the Congress of the European Hematology Association (EHA-2017)
  • 19 Jun 2017 Seattle Genetics suspends patient enrolment in a phase I/II trial in Myelodysplastic syndromes (Combination therapy, First-line therapy) in USA (NCT02706899)
  • 19 Jun 2017 Seattle Genetics terminates the phase III CASCADE trial in Acute myeloid leukaemia (Combination therapy, Newly diagnosed, First-line therapy, In adults, In the elderly) in USA, United Kingdom, Germany, Netherlands, Austria, Taiwan, South Korea, Spain, Luxembourg, Poland, Italy, Israel, France, Hungary, Czech republic, Belgium and Australia following consultation with the Independent Data Monitoring Committee (NCT02785900)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top